These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38664647)

  • 1. Fast Track Adaptation of Oncolytic Coxsackie B3 Virus to Resistant Colorectal Cancer Cells - a Method to Personalize Virotherapy.
    Elsner L; Heimann L; Geisler A; Dieringer B; Knoch KP; Hinze L; Klingel K; Solimena M; Kurreck J; Fechner H
    Biol Proced Online; 2024 Apr; 26(1):11. PubMed ID: 38664647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320.
    Girod M; Geisler A; Hinze L; Elsner L; Dieringer B; Beling A; Kurreck J; Fechner H
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
    Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
    Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas.
    Hazini A; Dieringer B; Pryshliak M; Knoch KP; Heimann L; Tolksdorf B; Pappritz K; El-Shafeey M; Solimena M; Beling A; Kurreck J; Klingel K; Fechner H
    Hum Gene Ther; 2021 Feb; 32(3-4):216-230. PubMed ID: 33481658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells.
    Pryshliak M; Hazini A; Knoch K; Dieringer B; Tolksdorf B; Solimena M; Kurreck J; Pinkert S; Fechner H
    FEBS Lett; 2020 Feb; 594(4):763-775. PubMed ID: 31643074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel.
    Lin Y; Liu N; Yang C; Tan H; Fang C; Yu K; Zhao H; Xia N; Wang W; Huang X; Cheng T
    Virol J; 2024 Oct; 21(1):245. PubMed ID: 39369233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.
    Hazini A; Dieringer B; Klingel K; Pryshliak M; Geisler A; Kobelt D; Daberkow O; Kurreck J; Linthout SV; Fechner H
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of a microRNA-Regulated Oncolytic Coxsackievirus B3.
    Dieringer B; Elsner L; Hazini A; Kurreck J; Fechner H
    Methods Mol Biol; 2022; 2521():259-282. PubMed ID: 35733003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas.
    Pinkert S; Pryshliak M; Pappritz K; Knoch K; Hazini A; Dieringer B; Schaar K; Dong F; Hinze L; Lin J; Lassner D; Klopfleisch R; Solimena M; Tschöpe C; Kaya Z; El-Shafeey M; Beling A; Kurreck J; Van Linthout S; Klingel K; Fechner H
    Cardiovasc Res; 2020 Aug; 116(10):1756-1766. PubMed ID: 31598635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coxsackievirus B3-Its Potential as an Oncolytic Virus.
    Geisler A; Hazini A; Heimann L; Kurreck J; Fechner H
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33919076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3.
    Liu H; Bahreyni A; Mohamud Y; Xue YC; Jia WWG; Luo H
    Mol Ther Oncolytics; 2022 Dec; 27():89-99. PubMed ID: 36321136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.
    Liu H; Xue YC; Deng H; Mohamud Y; Ng CS; Chu A; Lim CJ; Lockwood WW; Jia WWG; Luo H
    Mol Ther Oncolytics; 2020 Mar; 16():207-218. PubMed ID: 32123721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Sagara M; Miyamoto S; Itoh S; Soda Y; Tani K
    Anticancer Res; 2021 Jan; 41(1):81-89. PubMed ID: 33419801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
    Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
    Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
    Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
    Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extremely Low Organ Toxicity and Strong Antitumor Activity of miR-34-Regulated Oncolytic Coxsackievirus B3.
    Jia Y; Miyamoto S; Soda Y; Takishima Y; Sagara M; Liao J; Hirose L; Hijikata Y; Miura Y; Hara K; Iwanaga A; Ota Y; Tani K
    Mol Ther Oncolytics; 2019 Mar; 12():246-258. PubMed ID: 30891489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy.
    Bahreyni A; Liu H; Mohamud Y; Xue YC; Fan YM; Zhang YL; Luo H
    BMC Med; 2023 May; 21(1):193. PubMed ID: 37226233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Bahreyni A; Liu H; Mohamud Y; Xue YC; Zhang J; Luo H
    Cancer Lett; 2022 Nov; 548():215849. PubMed ID: 35995138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
    Liu S; Li F; Ma Q; Du M; Wang H; Zhu Y; Deng L; Gao W; Wang C; Liu Y; Zhao Z; Liu H; Wang R; Tian Y; Hu M; Wan Y; Lu W; Zhang M; Zhao M; Cao Y; Zhang H; Wang W; Wang H; Wang Y
    Theranostics; 2023; 13(12):4016-4029. PubMed ID: 37554264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.